Whereas in many cancer types blood-based markers have been developed to screen for disease recurrence, such as carcinoembryonic antigen (CEA) for colorectal cancer and prostate specific antigen (PSA) for prostate cancer [7,8], there are no clinically implemented tumor markers for sarcoma. This evidence concerns the gene KLK3 and prostate carcinoma.